A federal consultative group voted Thursday to loosen rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is not binding. The FDA has given no word on whether it will follow the advice. The move came after weeks of public comment sessions. Wellness backers advocated aggressively for wider access. RFK Jr. was among them. Critics say these compounds have little hard evidence of safety or help for most uses. The call could redefine how the agency handles a part of the wellness market that is scaling quickly. Patient groups are waiting to see if the FDA follows through on the vote. A spokesperson for the regulator offered no set date for a next move. Backers argue the change would widen access to substances some say help. Safety voices warn that looser rules could allow poor oversight across a wide-open market. The Thursday vote only clears a path to a change, and the final call rests with the regulator.